How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,200 results for

SGLT2 Inhibitor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Full Text available with Trip Pro

negative results of the PARAGON-HF primary end point analysis preclude any recommendation for the general use of sacubitril/valsartan in patients with HFpEF. The PARAGON-HF trial has provided a number of interesting insights; further analysis and investigation might inform future specific recommendations on the management of HFpEF. 4. New Evidence for SGLT2 Inhibitors and HF SGLT2 inhibitors lead to a reduction in plasma glucose by inhibiting renal tubular glucose reabsorption, with resultant (...) CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis - Canadian Journal of Cardiology Go search , P159-169, February 01, 2020 Powered By Mendeley CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation

2020 Canadian Cardiovascular Society

2. SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)

SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum) SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search SGLT2 inhibitors: reports (...) of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) If Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and start treatment urgently (including antibiotics and surgical debridement). Fournier’s gangrene is a rare but potentially life-threatening infection that requires urgent medical attention. Published 18 February 2019 From: Therapeutic area: , , , , , , Contents Advice for healthcare professionals: post-marketing cases of Fournier’s gangrene (necrotising fasciitis

2019 MHRA Drug Safety Update

3. SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions

SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions | Report | National Health Care Institute You are here: SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions Search within English part of National Health Care Institute Search SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions Zorginstituut Nederland has carried out (...) a substantive assessment of whether the existing list 2 conditions for SGLT2 inhibitors could be relaxed. This is a group assessment. The present question was whether patients who do not achieve their HbA1c target values despite a therapy including an optimally titrated basal-bolus insulin regimen would benefit from the addition of SGLT2 inhibitors. The Zorginstituut has now completed its assessment, after being advised by the Scientific Advisory Board. Advice Zorginstituut Nederland has concluded

2018 National Health Care Institute (Zorginstituut Nederland)

4. Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus

Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus Search > > Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus - Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus First published on 3 May 2017 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended (...) on the Medication Assistance Fund (MAF) for the abovementioned indications. MAF assistance does not apply to canagliflozin. Factors considered to inform the recommendation for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of SGLT2 inhibitors (that is, canagliflozin, dapagliflozin and empagliflozin) as part of a dual or triple oral therapy regimen for treating type 2 diabetes mellitus in November 2016

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

5. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information

SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information | European Medicines Agency Search Search Menu SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information Press release 24/02/2017 Diabetes patients reminded of importance of preventative foot care The European Medicines Agency (EMA (...) ) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin used for type 2 diabetes. Patients taking these medicines are reminded to check their feet regularly and follow their doctor's advice on routine preventative foot care. They should also tell their doctor if they notice any wounds or discoloration, or if their feet are tender or painful. The review of SGLT2 inhibitors

2017 European Medicines Agency - EPARs

6. Randomised controlled trial: SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Randomised controlled trial: SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease Article Text Therapeutics/Prevention Randomised controlled trial SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease André J Scheen

2017 Evidence-Based Medicine

7. SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee?

SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,600 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) October 30, 2017 SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee? Clinical Question: In patients with type 2 diabetes, do sodium-glucose co-transporter 2 (SGLT2) inhibitors affect mortality or cardiovascular disease (CVD)? Bottom-line: In diabetic patients at high-risk for CVD, empagliflozin reduces mortality for 1 in 39 patients at ~3 years (compared to placebo), while canagliflozin and empagliflozin both reduce CVD death, non-fatal myocardial infarction (MI), and stroke for ~1

2017 Tools for Practice

8. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)

SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) - GOV.UK GOV.UK uses cookies to make the site simpler. Search SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin (...) receiving any sodium-glucose co-transporter 2 (SGLT2) inhibitor about the importance of routine preventive foot care and adequate hydration continue to follow for routine preventive foot care for people with diabetes report any suspected side effect with SGLT2 inhibitors or any other medicine on a Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are indicated in adults with type 2 diabetes mellitus to improve glycaemic control when diet and exercise alone are inadequate for control. SGLT2

2017 MHRA Drug Safety Update

9. Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observ (Abstract)

Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observ 30136414 2019 01 11 1463-1326 21 2 2019 Feb Diabetes, obesity & metabolism Diabetes Obes Metab Comment on "Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure

2018 obesity & metabolism

10. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER Full Text available with Trip Pro

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation

2018 obesity & metabolism

11. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Full Text available with Trip Pro

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. To develop a quantitative drug-disease systems model to investigate the paradox that sodium-glucose co-transporter (SGLT)2 is responsible for >80% of proximal tubule glucose reabsorption, yet SGLT2 inhibitor treatment results in only 30% to 50% less reabsorption in patients with type 2 (...) diabetes mellitus (T2DM).A physiologically based four-compartment model of renal glucose filtration, reabsorption and excretion via SGLT1 and SGLT2 was developed as a system of ordinary differential equations using R/IQRtools. SGLT2 inhibitor pharmacokinetics and pharmacodynamics were estimated from published concentration-time profiles in plasma and urine and from urinary glucose excretion (UGE) in healthy people and people with T2DM.The final model showed that higher renal glucose reabsorption

2019 obesity & metabolism

12. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis Full Text available with Trip Pro

SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-analysis of 14 randomized controlled trials (RCTs) involving 4828 patients. Compared with a DPP-4 inhibitor, SGLT2 inhibitor/DPP-4 inhibitor combination (...) therapy was significantly associated with a decrease in glycaemic control (HbA1c, -0.71%; fasting plasma glucose [FPG], -25.62 mg/dL; postprandial plasma glucose, -44.00 mg/dL), body weight (-2.05 kg) and systolic blood pressure (-5.90 mm Hg), but an increase in total cholesterol (TC) of 3.24%, high-density lipoprotein of 6.15% and low-density lipoprotein of 2.55%. Adding a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, FPG by -8.94 mg/dL, TC by -1.48% and triglycerides by -3.25

2018 EvidenceUpdates

13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis Full Text available with Trip Pro

and inverse variance weighting were used to calculate relative risks with 95% confidence intervals.Data were obtained from 27 studies with up to 7363 participants involved. In patients with T2DM and CKD, SGLT2 inhibitors lowered glycated haemoglobin (-0.29%; 95% CI, -0.39 to -0.19) as well as blood pressure, body weight and albuminuria. SGLT2 inhibition reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR, 0.81; 95% CI, 0.70-0.94) and heart failure (RR, 0.61; 95 (...) Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and meta-analysis to assess the efficacy and safety

2019 EvidenceUpdates

14. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (Abstract)

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or transplantation or death due to kidney disease, is uncertain. Additionally, previous studies have been underpowered to robustly assess heterogeneity of effects on kidney outcomes by different levels of estimated glomerular filtration rate (eGFR (...) ) and albuminuria. We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors on major kidney outcomes in patients with type 2 diabetes and to determine the consistency of effect size across trials and different levels of eGFR and albuminuria.We did a systematic review and meta-analysis of randomised, controlled, cardiovascular or kidney outcome trials of SGLT2 inhibitors that reported effects on major kidney outcomes in people with type 2 diabetes. We searched MEDLINE

2019 EvidenceUpdates

15. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes

EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes | European Medicines Agency Search Search Menu EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes Press release 26/02/2016 Healthcare professionals should be aware of possible atypical cases The European Medicines Agency (EMA) has confirmed recommendations 1 (...) to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines). Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have been atypical, with patients not having blood sugar levels as high as expected. An atypical presentation of diabetic ketoacidosis

2016 European Medicines Agency - EPARs

16. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis (Abstract)

SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on risk of stroke have not been conclusively established. Therefore, we conducted a meta-analysis to evaluate the effects of SGLT2 inhibitors on stroke risk in patients with type 2 diabetes mellitus (T2DM) by searching available randomized trials in PubMed, Embase, CENTRAL, Web of Science, Scopus and ClinicalTrials.gov (...) databases. We identified 32 eligible trials involving 75 540 participants. The incidence of stroke in groups receiving SGLT2 inhibitor monotherapy or combination therapy did not differ significantly from that in control groups, with a relative risk (RR) of 1.01 and 1.0, respectively. Three SGLT2 inhibitors were tested, with similar RR values (canagliflozin [RR, 0.91], dapagliflozin [RR, 0.99] and empagliflozin [RR, 1.03]). Subgroup analyses showed that RR values were not affected by gender, age

2018 EvidenceUpdates

17. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (Abstract)

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined.We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome

2018 Lancet

18. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese Full Text available with Trip Pro

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese We investigated the effects of SGLT2 inhibitors vs DPP4 inhibitors on renal function preservation using real-world data of patients with type 2 diabetes in Japan, and identified which subgroups of patients showed greater benefits on renal (...) function preservation with SGLT2 inhibitors vs DPP4 inhibitors.We retrospectively analysed claims data recorded in the Medical Data Vision database in Japan of patients with type 2 diabetes (aged ≥18 years) prescribed any SGLT2 inhibitor or any DPP4 inhibitor between May 2014 and September 2016 (identification period), in whom estimated glomerular filtration rate (eGFR) was measured at least twice (baseline, up to 6 months before the index date; follow-up: 9-15 months after the index date

2019 obesity & metabolism

19. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Full Text available with Trip Pro

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short- and long-term follow-up in patients with T2DM who were inadequately controlled with metformin (≥1500

2019 obesity & metabolism Controlled trial quality: uncertain

20. Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). Full Text available with Trip Pro

Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). This multicentre, prospective, randomized, open-label, blinded-endpoint, parallel-group, short-term (4-5 weeks) controlled trial was conducted to investigate the superiority of the effect of reducing mean amplitude of glycaemic excursions (MAGE) during meal tolerance tests (...) (MTTs) for the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor compared with SGLT2 inhibitor monotherapy. Ninety-nine patients with type 2 diabetes who were taking teneligliptin (20 mg/d) were randomized to one of the following two groups: those who switched to 100 mg/d of canagliflozin (SWITCH group) or those who added 100 mg/d of canagliflozin (COMB group). MAGE in the COMB group was significantly decreased compared

2019 obesity & metabolism

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>